Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
The evidence from the AFFIRM study shows that natalizumab significantly reduces the probability of sustained disability progression and annualized relapse rates compared to placebo, with hazard ratios indicating a strong clinical effect. However, the lack of direct comparisons with beta interferon and glatiramer acetate limits the robustness of the evidence for the suboptimal therapy group.
Cost effectiveness
The ICERs for natalizumab compared to beta interferon and best supportive care are within acceptable ranges, suggesting it is marginally cost-effective. However, the committee expressed concerns about the potential overestimation of ICERs due to uncertainties in the model.
Quality of life
Natalizumab demonstrated significant improvements in health-related quality of life as measured by the SF-36 instrument, although results were not consistent across all measures, indicating moderate but meaningful gains.
Supporting Domains
Safety and Adverse Effects
Natalizumab has a very good safety profile, with no higher incidence of adverse events compared to placebo and a statistically significant reduction in certain adverse events compared to beta interferon.
Comparator Selection
The manufacturer used indirect comparisons with beta interferon and glatiramer acetate, which were not ideal due to the lack of direct evidence. The committee noted that the comparators were not fully representative of the RES group.
Patient Population and Subgroups
The trial population included a relevant subgroup of patients with highly active relapsing-remitting multiple sclerosis, although there are concerns regarding the generalizability of findings to the suboptimal therapy group.
Care Pathway Integration
Natalizumab can be integrated into existing care pathways with minor adjustments, as it is administered in a familiar setting (intravenous infusion) and does not require extensive new infrastructure.
Resource Use and Cost Implications
The budget impact is manageable, and the therapy is expected to provide significant benefits relative to its costs, although there are concerns about the overall resource burden.
Evidence Quality and Robustness
The evidence is primarily based on the robust AFFIRM study and supported by additional data, although there are some methodological concerns regarding the indirect comparisons.
Uncertainty, Sensitivity, and Broader Impacts
There are significant uncertainties regarding the long-term effectiveness and cost-effectiveness due to reliance on indirect comparisons and assumptions in the economic model.
